These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26472573)

  • 1. The Impact of Physical Activity on Mitigation of Health Care Costs Related to Diabetes Mellitus: Findings from Developed and Developing Settings.
    Turi BC; Monteiro HL; Fernandes RA; Codogno JS
    Curr Diabetes Rev; 2016; 12(4):307-311. PubMed ID: 26472573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
    Wolfenstetter SB
    Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of physical inactivity: healthcare costs associated with cardiovascular disease.
    Oldridge NB
    Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):130-9. PubMed ID: 18391637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease and Economic Burden of Hospitalizations Attributable to Diabetes Mellitus and Its Complications: A Nationwide Study in Brazil.
    Rosa MQM; Rosa RDS; Correia MG; Araujo DV; Bahia LR; Toscano CM
    Int J Environ Res Public Health; 2018 Feb; 15(2):. PubMed ID: 29419786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polish Multicenter Study on Diabetes Epidemiology (PMSDE)--1998-2000].
    Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):751-8. PubMed ID: 11928582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses.
    Alzaid A; Ladrón de Guevara P; Beillat M; Lehner Martin V; Atanasov P
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):785-798. PubMed ID: 32686530
    [No Abstract]   [Full Text] [Related]  

  • 7. Five-Year Cost-effectiveness of the Multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM).
    Jiao FF; Fung CSC; Wan EYF; Chan AKC; McGhee SM; Kwok RLP; Lam CLK
    Diabetes Care; 2018 Feb; 41(2):250-257. PubMed ID: 29246949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of type 2 diabetes mellitus and physical activity on medication costs in older adults.
    Kikuti-Koyama KA; Monteiro HL; Ribeiro Lemes Í; de Morais LC; Fernandes R; Turi-Lynch B; Codogno J
    Int J Health Plann Manage; 2019 Oct; 34(4):e1774-e1782. PubMed ID: 31435976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost of treating type 2 diabetes (CODEIRE).
    Nolan JJ; O'Halloran D; McKenna TJ; Firth R; Redmond S
    Ir Med J; 2006; 99(10):307-10. PubMed ID: 17274175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictions Burden of Diabetes and Economics Cost: Contributing Risk Factors of Changing Disease Prevalence and its Pandemic Impact to Qatar.
    Bener A; Al-Hamaq AO
    Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):504-511. PubMed ID: 27023007
    [No Abstract]   [Full Text] [Related]  

  • 11. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
    van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
    Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of Type 2 Diabetes mellitus in Hong Kong Chinese.
    Chan BS; Tsang MW; Lee VW; Lee KK
    Int J Clin Pharmacol Ther; 2007 Aug; 45(8):455-68. PubMed ID: 17725179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes in Japan: a review of disease burden and approaches to treatment.
    Neville SE; Boye KS; Montgomery WS; Iwamoto K; Okamura M; Hayes RP
    Diabetes Metab Res Rev; 2009 Nov; 25(8):705-16. PubMed ID: 19795421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current total economic burden of diabetes mellitus in the Netherlands.
    Peters ML; Huisman EL; Schoonen M; Wolffenbuttel BHR
    Neth J Med; 2017 Sep; 75(7):281-297. PubMed ID: 28956787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Projecting prevalence, costs and evaluating simulated interventions for diabetic end stage renal disease in a Canadian population of aboriginal and non-aboriginal people: an agent based approach.
    Gao A; Osgood ND; Jiang Y; Dyck RF
    BMC Nephrol; 2017 Sep; 18(1):283. PubMed ID: 28870154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes in numbers.
    Scully T
    Nature; 2012 May; 485(7398):S2-3. PubMed ID: 22616094
    [No Abstract]   [Full Text] [Related]  

  • 18. Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases.
    Scalone L; Cesana G; Furneri G; Ciampichini R; Beck-Peccoz P; Chiodini V; Mangioni S; Orsi E; Fornari C; Mantovani LG
    PLoS One; 2014; 9(12):e113741. PubMed ID: 25470484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time and cost involved in the care of newly registered patients with diabetes mellitus and other lifestyle diseases at diabetes clinics in Japan (JDDM 4).
    Oishi M; Yokoyama H; Abe N; Iwasaki K; Okuguchi F; Kawai K; Sugimoto H; Takamura H; Takeda H; Doi K; Hirao K; Ikeda S
    Diabet Med; 2007 Oct; 24(10):1149-55. PubMed ID: 17888135
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.